That Namenda hard switch Actavis wants? It could cost HHS $6B

Actavis ($ACT) said last month it stood to lose $200 million in sales if an appeals court didn't let it force patients over to a new, patent-protected version of Alzheimer's treatment Namenda before generics hit. But if it does? The Department of Health and Human Services (HHS) predicts it'll cost the federal government $6 billion at the least. More from FiercePharma